MX2009003821A - Compuestos de n-aril pirazol para usarse contra la diabetes. - Google Patents

Compuestos de n-aril pirazol para usarse contra la diabetes.

Info

Publication number
MX2009003821A
MX2009003821A MX2009003821A MX2009003821A MX2009003821A MX 2009003821 A MX2009003821 A MX 2009003821A MX 2009003821 A MX2009003821 A MX 2009003821A MX 2009003821 A MX2009003821 A MX 2009003821A MX 2009003821 A MX2009003821 A MX 2009003821A
Authority
MX
Mexico
Prior art keywords
use against
pyrazole compounds
against diabetes
aryl pyrazole
diabetes
Prior art date
Application number
MX2009003821A
Other languages
English (en)
Inventor
Xiaolin Hao
Sarah E Lively
Zice Fu
Ryo Okuyama
Yasuyuki Ogawa
Satoshi Shibuya
Narihiro Toda
Zhaodan Cao
Yong-Jae Kim
Leping Li
Mike Lizarzaburu
Hui Tian
Ming Yu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2009003821A publication Critical patent/MX2009003821A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan aquí los compuestos que tienen la fórmula I, donde A1, A2, L, V, W, R1, R2, R3, R4 y R5 son como se describe aquí, las composiciones de los mismas, y su uso para el tratamiento o prevención de la diabetes tipo 2 y condiciones relacionadas con la diabetes tipo 2.
MX2009003821A 2006-10-10 2007-10-09 Compuestos de n-aril pirazol para usarse contra la diabetes. MX2009003821A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85108306P 2006-10-10 2006-10-10
PCT/US2007/021678 WO2008045484A1 (en) 2006-10-10 2007-10-09 N-aryl pyrazole compounds for use against diabetes

Publications (1)

Publication Number Publication Date
MX2009003821A true MX2009003821A (es) 2009-05-25

Family

ID=39047570

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003821A MX2009003821A (es) 2006-10-10 2007-10-09 Compuestos de n-aril pirazol para usarse contra la diabetes.

Country Status (12)

Country Link
US (1) US8022061B2 (es)
EP (1) EP2079728B1 (es)
JP (1) JP2010505957A (es)
AR (1) AR063240A1 (es)
AU (1) AU2007308154A1 (es)
CA (1) CA2675511A1 (es)
CL (1) CL2007002904A1 (es)
ES (1) ES2430821T3 (es)
MX (1) MX2009003821A (es)
PE (1) PE20080858A1 (es)
TW (1) TW200831491A (es)
WO (1) WO2008045484A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2493155C2 (ru) 2006-12-08 2013-09-20 Ф.Хоффманн-Ля Рош Аг Замещенные пиримидины и их применение в качестве модуляторов jnk
ES2551095T3 (es) 2007-07-19 2015-11-16 Lundbeck, H., A/S Amidas heterocíclicas de 5 miembros y compuestos relacionados
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2008296974B2 (en) 2007-09-06 2013-10-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
MX2011008952A (es) 2009-02-26 2011-09-27 Merck Sharp & Dohme Activadores de guanilato ciclasa solubles.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011146354A1 (en) * 2010-05-20 2011-11-24 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
EA023254B1 (ru) 2010-05-27 2016-05-31 Мерк Шарп Энд Домэ Корп. Активаторы растворимой гуанилатциклазы
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
JP5605104B2 (ja) * 2010-09-10 2014-10-15 セントラル硝子株式会社 ピラゾール化合物の製造方法
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2893597C (en) 2012-12-07 2021-06-29 Chemocentryx, Inc. Diazole lactams
EP2935227B1 (en) 2012-12-21 2017-09-13 ChemoCentryx, Inc. Diazole amides as ccr1 receptor antagonists
CN103772282B (zh) * 2014-02-26 2015-09-23 上海毕得医药科技有限公司 一种3-叔丁基-1h-吡唑-4-甲醛的制备方法
WO2016138631A1 (en) 2015-03-03 2016-09-09 Eli Lilly And Company Imidazo benzamide compounds
SG10201913587WA (en) * 2016-02-05 2020-02-27 Denali Therapeutics Inc Inhibitors of receptor-interacting protein kinase 1
EP3439653B1 (en) 2016-04-07 2021-01-20 ChemoCentryx, Inc. Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
ES2912295T3 (es) 2016-12-09 2022-05-25 Denali Therapeutics Inc Compuestos útiles como inhibidores de RIPK1
WO2019194207A1 (ja) * 2018-04-04 2019-10-10 日本たばこ産業株式会社 ヘテロアリールで置換されたピラゾール化合物及びその医薬用途
WO2020007729A1 (en) 2018-07-04 2020-01-09 Boehringer Ingelheim International Gmbh Triazole benzamide derivatives as gpr142 agonists
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE
US11999750B2 (en) 2022-01-12 2024-06-04 Denali Therapeutics Inc. Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3778433A (en) 1969-04-18 1973-12-11 Sumitomo Chemical Co Process for producing benzodiazepine derivatives
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPH04145081A (ja) 1990-10-06 1992-05-19 Kumiai Chem Ind Co Ltd ピラゾールカルボン酸誘導体及び除草剤
TW312694B (es) 1994-09-26 1997-08-11 Daiichi Seiyaku Co
US5883105A (en) 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2002514195A (ja) 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジン化合物およびそれの使用
US6169086B1 (en) 1997-01-27 2001-01-02 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives
AU725548B2 (en) 1997-03-11 2000-10-12 E.I. Du Pont De Nemours And Company Heteroaryl azole herbicides
WO2001087849A2 (en) 2000-05-12 2001-11-22 Genzyme Corporation Modulators of tnf- alpha signaling
EP1329160A4 (en) 2000-08-25 2004-04-14 Sankyo Co 4-ACYLAMINOPYRAZOL DERIVATIVES
US20040198758A1 (en) 2001-08-17 2004-10-07 Rapado Liliana Parra N-heterocyclyl substituted thienyloxy-pyrimidines used as herbicides
CA2465207C (en) 2001-11-01 2011-01-04 Icagen, Inc. Pyrazole-amides and -sulfonamides
DE10234876A1 (de) 2002-07-25 2004-02-05 Bayer Cropscience Gmbh 4-Trifluormethylpyrazolyl substituierte Pyridine und Pyrimidine
JP3774184B2 (ja) 2002-10-25 2006-05-10 株式会社フジクラ 光ファイバ心線テープ被覆除去具及び光ファイバ心線テープ被覆除去方法
EP1620108B1 (en) 2003-05-01 2012-06-06 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
JP2004339080A (ja) 2003-05-13 2004-12-02 Tokyo Institute Of Technology ピラゾ−ル誘導体を含有する高血圧治療剤
US6818631B1 (en) 2003-08-15 2004-11-16 Nippon Soda Co. Ltd. Fungicidal pyrimidine derivatives
BRPI0417478A (pt) 2003-12-15 2007-05-08 Almirall Prodesfarma Ag 2,6-bis-heteroaril-4-aminopirimidinas como antagonistas de receptor de adenosina
MXPA06012394A (es) 2004-04-30 2007-01-31 Bayer Pharmaceuticals Corp Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
WO2007008541A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
US20090275586A1 (en) * 2006-10-06 2009-11-05 Kalypsys, Inc. Heterocyclic inhibitors of pde4

Also Published As

Publication number Publication date
JP2010505957A (ja) 2010-02-25
US8022061B2 (en) 2011-09-20
ES2430821T3 (es) 2013-11-21
AR063240A1 (es) 2009-01-14
CL2007002904A1 (es) 2008-06-06
EP2079728B1 (en) 2013-09-25
CA2675511A1 (en) 2008-04-17
PE20080858A1 (es) 2008-08-06
TW200831491A (en) 2008-08-01
WO2008045484A1 (en) 2008-04-17
US20080153778A1 (en) 2008-06-26
EP2079728A1 (en) 2009-07-22
AU2007308154A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
MX2009003821A (es) Compuestos de n-aril pirazol para usarse contra la diabetes.
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
WO2007106192A3 (en) Inhibitors of iap
WO2009016462A3 (en) Substituted bicyclolactam compounds
RS20090249A (en) Spiroketone acetyl-coa carboxylase inhibotors
WO2007140385A3 (en) Thiazole compounds as cannabinoid receptor ligands and uses thereof
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
WO2009027820A3 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
WO2008107478A8 (en) Quinolinone derivatives as parp and tank inhibitors
MX2009007345A (es) Compuestos con (fenil sustituido), con restos de propenal, sus derivados, actividad biologica y uso del mismo.
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
PT1902037E (pt) 2,4-diamino-pirimidinas como inibidores de aurora
GB0625648D0 (en) Compounds
MX2009010960A (es) Compuestos heterociclicos y sus metodos de uso.
MX2009007713A (es) Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
WO2007097981A3 (en) Alpha carbolines and uses thereof
WO2009046842A3 (de) Thialzolderivate zur behandlung von krebs
WO2009085277A3 (en) Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
MX2010008226A (es) Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
SG151306A1 (en) Novel benzothiazoles and the use thereof as medicaments
WO2008073332A3 (en) Creatine compositions for skin treatment

Legal Events

Date Code Title Description
HH Correction or change in general